Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aimovig Priced ‘Well Below’ Part D Specialty Threshold To Avoid Coinsurance

Executive Summary

Amgen-Novartis pricing strategy seeks to ensure patients are subject to flat copays rather than coinsurance, which is calculated as a percentage of drug's list price.

You may also be interested in...



Trump Expecting Rx Price Reduction Announcements In Two Weeks

Look for Administration to take credit for any positive pricing news as President says several firms will 'announce voluntary massive drops in prices.'

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

Amgen and Novartis won the first US FDA approval for a CGRP inhibitor in the prevention of migraine headaches. The companies aim to quickly capture a big share of what they estimate to be an 8m-patient market in the US with a $6,900 per year price tag.

New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests

Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.

Topics

Related Companies

UsernamePublicRestriction

Register

PS123157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel